使用肉汤圆盘洗脱试验评估氨苄西林-舒巴坦和头孢哌酮-舒巴坦对鲍曼不动杆菌的体外活性,在2019年1月至2021年1月期间,从中国各地共收集到150株鲍曼不动杆菌分离株,包括51株碳青霉烯类敏感株和99株碳青霉烯类耐药株.对所有菌株进行肉汤圆盘洗脱(BDE)和肉汤微量稀释(BMD)方法。BDE的浓度范围为10/10µg/mL,20/20µg/mL,氨苄西林-舒巴坦为30/30µg/mL,和37.5/15µg/mL,75/30µg/mL,112.5/45µg/mL,头孢哌酮-舒巴坦为150/60µg/mL,分别。与BMD相比,氨苄西林-舒巴坦和头孢哌酮-舒巴坦的溴二苯醚结果分别为83.3%(125/150)和95.3%(143/150),小误差为16.7%(25/150)和4.7%(7/150),分别。未检测到重大错误或非常重大的错误。耐碳青霉烯类鲍曼不动杆菌(CRAb)对不同浓度氨苄西林-舒巴坦的BDE敏感性差异有统计学意义(p<0.017)。而头孢哌酮-舒巴坦的浓度为37.5/15µg/mL,75/30µg/mL,和112.5/45µg/mL显著(p<0.008)。然而,在112.5/45µg/mL和150/60µg/mL之间没有观察到灵敏度的显著差异(p>0.008).总之,BDE是检测头孢哌酮-舒巴坦对鲍曼不动杆菌的体外活性的可靠和方便的方法,结果可作为决定是否使用大剂量舒巴坦治疗鲍曼不动杆菌感染的临床参考价值。
To evaluate the in vitro activity of ampicillin-sulbactam and
cefoperazone-sulbactam against A. baumannii using the broth disk elution testing, a total of 150 A. baumannii isolates were collected from across China between January 2019 and January 2021, including 51 carbapenem-susceptible and 99 carbapenem-resistant isolates. Broth disk elution (BDE) and the broth microdilution (BMD) method were performed for all strains. The concentration range of the BDE was 10/10 µg/mL, 20/20 µg/mL, and 30/30 µg/mL for ampicillin-sulbactam, and 37.5/15 µg/mL, 75/30 µg/mL, 112.5/45 µg/mL, and 150/60 µg/mL for
cefoperazone-sulbactam, respectively. Compared with BMD, the BDE results of ampicillin-sulbactam and
cefoperazone-sulbactam showed a categorical agreement of 83.3% (125/150) and 95.3% (143/150), with minor errors of 16.7% (25/150) and 4.7% (7/150), respectively. No major error or very major errors were detected. The sensitivity differences by BDE of carbapenem-resistant A. baumannii (CRAb) to different concentrations of ampicillin-sulbactam showed statistically significant (p < 0.017), while those to
cefoperazone-sulbactam at 37.5/15 µg/mL, 75/30 µg/mL, and 112.5/45 µg/mL were significant (p < 0.008). However, no significant difference in sensitivity was observed between 112.5/45 µg/mL and 150/60 µg/mL (p > 0.008). In conclusion, the BDE is a reliable and convenient method to detect the in vitro activity of
cefoperazone-sulbactam against A. baumannii, and the results could serve as a clinical reference value when deciding whether or not to use high-dose sulbactam for the treatment of A. baumannii infections.